Natco Pharma is building infrastructure capabilities to meet its future needs. The company is planning to establish facility for cytotoxic APIs, which is expected to be operational by mid-2007.
Also, with the new production block in the company's API facility coming into operation, revenues from this division are also expected to get a boost.
The API division has been, of late, facing pressure on realizations, with a steep drop in prices of certain key products. On the other hand, the finished dosage formulations division has grown, recording a growth of a little over 12 per cent.
The revenues from the oncology segment continues to be robust, nearing the Rs 5 crore per month mark.
Natco has already secured second position in the oncology segment among the Indian companies, in terms of revenues and with a few more launches slated in the coming months, expect to reach the top league.
During the fiscal 2007, revenues from the oncology segment alone are likely to be in the region of Rs 70 crore.
Natco which has recently forayed into the retail market in US, is proposing to expand its base in the US with further acquisitions in the retail segment.
Revenues from this segment alone are expected to cross the US $ 50 million mark, on an annual basis, with the planned acquisitions taking place.
The gradual shifting of all finished dosage pharmaceutical formulations to Dehradun is expected to result in substantial savings accruing to the bottom line in the fiscal 2007.